Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes

US8389493B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Larry R. Brown · Newton, US
• Nick Giannoukakis · Pittsburgh, US
• Kimberly Gillis · Beverly, US
• Massimo M. Trucco · Pittsburgh, US

Key dates

• Filing date: May 9, 2011
• Grant date: Mar 5, 2013
• Expiry date: May 9, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.